MELBOURNE: IonOpticks is entering an exciting new phase of expansion, having outgrown its existing facilities in recent months. To accommodate this progress, the company has taken on a new lease and appointed builder David Murphy of Challenge Group to construct a purpose-built facility in Melbourne, designed thoughtfully and responsibly by JMA Architects.

L to R: Property and Facilities Project Manager, David Sinden; Chief Executive Officer Xavier Perronnet; Chief Brand Officer, Michael Sinden; Managing Director, Challenge Group, David Murphy.

The stunning art-deco premises in Melbourne’s inner east will see the fit-out span two floors and house IonOpticks’ bespoke manufacturing facility, R&D laboratory, and corporate headquarters. The contemporary and sustainable design reflects the company’s commitment to innovation and excellence, ensuring that this new home will support its ambitions for years to come. IonOpticks’ Chief Brand Officer, Michael Sinden said of the plans:

“I’m incredibly excited to see this major project underway for IonOpticks. It’s a significant milestone for us and reinforces to both our staff and our customers that we’re always in pursuit of continuous innovation and improvement. Personally, I can’t wait to see how this new space will inspire our team and accelerate our development into the future.”

A vital step in strengthening the company’s market position, the project advances ambitious development plans and provides another solid foundation for IonOpticks towards its goal: to enable transformative human health advancements by democratising elite-level chromatographic tools for labs worldwide, as Chief Executive Officer Xavier Perronnet explains:

“This is a momentous period for the company and our team, as we embark on this next chapter. The new facility will not only increase our manufacturing capacity but also provide a dedicated space for research and development, fuelling the continued collaboration and creativity that has delivered us our rapid success.”

By investing in this new infrastructure, the company is well-positioned to meet the growing demand for its products and services, ensuring that it continues to lead in the field of chromatography. As plans progress, IonOpticks looks forward to the opportunities this new facility will bring and the impact it will have on its ability to innovate and grow. More updates to follow as the project develops.

About IonOpticks:
IonOpticks produces high-performance nanoflow chromatography solutions for the global research community. They specialize in the development and manufacture of columns for analytical applications in liquid chromatography with mass spectrometry (LC-MS) and high-end proteomics. Their highly reproducible methods provide a unique ability to enhance the sensitivity of mass spectrometry sample analysis, enabling scientists and clinicians to discover more from their samples. The IonOpticks team are experts in a broad array of LC-MS platform technologies and are driven by the need to improve chromatographic performance in order to achieve data quality and deep proteome coverage on a whole new scale. IonOpticks columns are used for a broad range of applications within the field of biological and medical research including drug discovery, phosphoproteomics and shotgun proteomics. When powered by IonOpticks, the possibilities are endless.